News | Stem Cell Therapies | June 12, 2017

Research Reveals New Insights Into Why Heart Does Not Repair Itself

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that heart disease is the leading cause of death for both men and women in the United States, according to the Centers for Disease Control and Prevention. Inspired by the idea of helping the heart repair itself, researchers at Baylor College of Medicine and the Texas Heart Institute have studied pathways known to be involved in heart cell functions and discovered a previously unknown connection between processes that keep the heart from repairing itself. This finding, published in the journal Nature, opens the possibility of developing strategies that will promote heart cell renewal in the future.

“We are investigating the question of why the heart muscle doesn’t renew,” said senior author James Martin, M.D., professor and Vivian L. Smith Chair in Regenerative Medicine at Baylor College of Medicine. “In this study, we focused on two pathways of cardiomyocytes or heart cells: the Hippo pathway, which is involved in stopping renewal of adult cardiomyocytes, and the dystrophin glycoprotein complex (DGC) pathway, essential for cardiomyocyte normal functions. We are also interested in studying mutations in DGC components because patients with these mutations have a muscle wasting disease called muscular dystrophy.”

Previous work had hinted that components of the DGC pathway may somehow interact with members of the Hippo pathway. In this study, Martin and colleagues studied the consequences of this interaction in animal models. The researchers genetically engineered mice to lack genes involved in one or both pathways, and then determined the ability of the heart to repair an injury. These studies showed for the first time that dystroglycan 1, a component of the DGC pathway, directly binds to Yap, part of the Hippo pathway, and that this interaction inhibited cardiomyocyte proliferation.

“The discovery that the Hippo and the DGC pathways connect in the cardiomyocyte and that together they act as ‘brakes,’ or stop signals to cell proliferation, opens the possibility that by disrupting this interaction one day it might be possible to help adult cardiomyocytes proliferate and heal injuries caused by a heart attack, for example,” Martin said.

Another long-term application of this discovery could be to improve cardiac function in children with muscular dystrophy.

“Patients with muscular dystrophy can have severe reduction in cardiac function,” Martin said. “Our findings may help to design medicines to slow down cardiac decline in muscular dystrophy by stimulating cardiomyocyte proliferation. In order to do that, we need more research to understand cardiomyocyte growth control pathways in greater detail.”

Other contributors to this work include Yuka Morikawa, Todd Heallen, John Leach and Yang Xiao.

This project was supported in part by an Intellectual and Developmental Disability Research Center grant (1U54 HD083092) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the Mouse Phenotyping Core at Baylor College of Medicine with funding from the National Institutes of Health (U54 HG006348); and grants from the National Institutes of Health (DE 023177, HL 127717, HL 130804, and HL 118761) and the Vivian L. Smith Foundation. Support was also provided by the Transatlantic Network of Excellence Award LeDucq Foundation Transatlantic Networks of Excellence in Cardiovascular Research 14CVD01 and the American Heart Association Scientist Development Grant 16SDG26460001.

For more information: www.bcm.edu/news

Related Content

Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies | September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies | August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Stem Cell Therapy Holds Promise for Treating Most Severe Cases of Angina
News | Stem Cell Therapies | May 12, 2017
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies | April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies | February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
News | Stem Cell Therapies | January 09, 2017
BioCardia Inc. announced in December the issuance of United States Patent No. 9,517,199 relating to a method of...
News | Stem Cell Therapies | January 03, 2017
January 3, 2017 — BioCardia Inc. announced in December the initiation of the CardiAMP Heart Failure pivotal trial, a
Overlay Init